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See related letters by Rashid et al., http://ccforum.com/content/18/1/401, and Honoré et al., http://ccforum.com/content/18/1/412, and related research
by Rocco et al. http://ccforum.com/content/17/4/R174We thank Rashid and colleagues [1] and Honoré
and colleagues [2] for their comments regarding our
article on risk factors for acute kidney injury in pa-
tients receiving colistin or other nephrotoxic antimi-
crobials [3].
It is correct that we did not specifically report urine
output in the text, but it was obviously included in the
RIFLE (Risk, Injury, Failure, Loss of kidney function,
and End-stage kidney disease) criteria reported in
Table two [3].
We agree that the colistin methanesulfonate pharma-
cokinetics have been better studied recently, and it has
become clear that high doses are required for treating
multidrug-resistant Gram-negative bacilli infection,
including the loading dose (which has changed from 4
to 9 million IU) and the dose interval (which has
changed from three to two times a day) [4]. We agree
with the authors’ concerns about the adequacy of
colistin dosages adopted in our cohort (130,000 IU/kg
of ideal body weight, modified according to renal
function), but these doses were commonly adopted,
especially in patients with renal impairment [5].
Indeed, the development of new high-performance
liquid chromatography assays that allow clinicians to
measure the concentrations of colistimethate and
colistin separately has shown that colistin clearance is
due mainly to non-renal mechanisms that are still
unclear. It is of great interest to note, as reported re-
cently by Honoré and colleagues [6], that patients with
multidrug-resistant infections can receive even higher
doses of colistin during continuous renal replacement
therapy, as colistin methanesulfonate is continuously
filtered and absorbed by dialysis membrane [7]. Hence,
even higher doses may be needed in patients receiving
continuous renal replacement therapy than in patients
with normal renal function. The growing evidence in* Correspondence: monica.rocco@uniroma1.it
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